A new boron compound (Guanidine biboric acid adduct) as an antitumour agent against Ehrlich ascites carcinoma in mice

Tumor Biology

Volumn 20, Issue 1, 1999, Pages 44-51

  Ghosh, P ^a   Sur, B ^a   Bag, S P ^a   Sur, Pratima ^a,b  

^a JADAVPUR UNIVERSITY   (India)

^b INDIAN INSTITUTE OF CHEMICAL BIOLOGY   (India)

Author keywords

5 Fluorouracil; Boron compound; Ehrlich ascites cells

Indexed keywords

ANTINEOPLASTIC AGENT; BORON DERIVATIVE; FLUOROURACIL; GUANIDINE; GUANIDINE BIBORIC ACID; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOASSAY; BLOOD CELL COUNT; CANCER INHIBITION; CONTROLLED STUDY; DNA SYNTHESIS; DRUG SYNTHESIS; EHRLICH ASCITES TUMOR; FEMALE; LD 50; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL TIME;

EID: 0032911687     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1159/000056520     Document Type: Article

References (16)

1. Das MK, Maity KP, Roy S, Mittakanti M, Morse WK, Hall TH: Relationship of hypolipidemic and antineoplastic activities of tricyclohexyl and triphenyl phosphine borane, carboxyboranes, cyanoboranes and related derivatives. Arch Pharm (Weinheim) 1972;325:267-272.
2. Soloway AH, Wyzlic IM, Hariharan JR, Barth RF: Development of boron containing polyamines for DNA targeting in BNCT. Am Assoc Cancer Res 1995;36:300.
3. Hall IH, Das MK, Harchelroad F Jr, Nelson PW, Mephail AT, Spielvogel BF: Antihyperlipidemic activity of amine cyanoboranes. Amine carboxyboranes and related compounds. J Pharm Sci 1981;70:339-341.
4. Sood A, Sood CK, Spielvogel BF, Hall IH: Boron analogues of glycine and derivatives. Eur J Med Chem 1990;25:301.
5. Lin PS, Kwock L, Ciborowski L, Butlerfield C: Sensitization effects of diethyldithiocarbamate. Radiat Res 1978;74:515-516.
6. Ferreira ST, Stella L, Gratton E: Conformational dynamics of bovine Cu-Zn-superoxide dismutase by time resolve fluorescence spectroscopy of the single tyrosine residue. Biophys J 1994;66:1185-1196.
7. Bag SP, Ghosh P, Sur B, Sur P: Synthesis and characterization of new boron compounds - Guanidine boron adduct and hydroxamato boron. Indian J Chem Soc 1998;75:43-44.
8. Litehifield JT, Wilcoxon FA: Simplified method of evaluating dose effect experiments. J Pharmacol Exp Ther 1949;96:99-102.
9. Sur P, Ganguly DK: Tea plant root extract (TRE) as an antineoplastic agent. Planta Med 1994;60:106-109.
10. Fernands DJ, Klubes P: Study of therapeutic murine L1210 leukemia. Cancer Res 1979;39:1396-1404.
11. Sur P, Matsuo Y, Otani T, Minowada J: Modulation of methotrexate cytotoxicity with natural interferon upon human leukemia cell line HL-60. Oncology 1991;48:469-473.
12. Kolmer JA, Spaulding EH, Robinson HW: Approved Laboratory Technic, ed 5. New York, Appleton Century Crofts, 1969, pp 39-126.
13. Ghosh P, Bag SP, Sur B, Sur P: Antitumor properties of boron complexes with hydroxy biguanide and salicyl hydroxamic acid against Ehrlich ascites carcinoma. Neoplasma 1998;45:68-72.
14. Hall IH, Starnes CO, Spielvogel BF, Neilson PW, Das MK, Wojnowich L: Boron betaine analogs. Antitumour activity and effects on Ehrlich ascites tumour cell metabolism. J Pharm Sci 1979;68:685-688.
15. Hall IH, Spielvogel BF, Sood A: The antineoplastic activity of trimethylamine carboxyboranes and related esters and amides in murine and human tumour cell lines. Anticancer Drugs 1990;1:133-141.
16. Hall IH, Hall ES, Chi LK, Shaw BR, Sood A, Spielvogel BF: Antineoplastic activity of boron containing thymidine nucleosides in Tmolt3 leukemic cells. Anticancer Res 1992; 12:1091-1097.